We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genotyping Assay Integrated into Glioma Treatment

By LabMedica International staff writers
Posted on 22 Aug 2018
Stage II diffuse gliomas are normally challenging to identify using intraoperative histologic methods because of their location, infiltrative growth, low cellularity, and small stereotactic biopsy size. More...
Diagnosis often requires the patient to undergo multiple neurosurgical procedures to collect tumor tissue samples.

A rapid multiplexed polymerase chain reaction (PCR)-based genotyping tool has been developed to diagnose patients with a mutated brain tumor cell line during surgery, which could be used in tandem with a therapeutic tool to eradicate the glioma. Lower-grade gliomas are often characterized by mutations in metabolism-related genes isocitrate dehydrogenase 1 (IDH1) and IDH2.

A large team of scientists led by those at the Harvard Medical School (Boston, MA, USA) first characterized the patterns of IDH mutant glioma progression by analyzing a cohort of 130 patients who underwent resection. Afterwards, they integrated the genotyping tool with the drug delivery system on glioma tissue samples resected from neurosurgery operations to develop a prototype for the proposed combined surgical model. By suppressing wild-type alleles, the team detected mutations in IDH1, Telomerase Reverse Transcriptase (TERT) promoter mutations, H3 Histone Family Member 3A (H3F3A), and BRAF within 27 minutes.

The team then validated the genetic diagnostic tool on extracted human samples, testing the assay on 87 clinically annotated brain tumors. They found that the presence of at least one or more mutations in captured 75 brain tumor samples, noting in their paper that the high rate of positive assignment allows for the confidence to distinguish tumor versus nonneoplastic pathologies.

Daniel P. Cahill, MD, PhD, a neurology associate professor and senior author of the study, said, “We have found that a high frequency of cases can be classified correctly by scoring a handful of these point mutations. We suggested an opportunity, where we could, through an optimized PCR technique, prove a clinically useful categorizing technology in a rapid way.” The continuation study was published on August 6, 2018, in the journal Proceedings of National Academy of Sciences.

Related Links:
Harvard Medical School


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.